Structural basis of intracellular TGF-β signaling: Receptors and smads

Cold Spring Harbor Perspectives in Biology

Volumn 8, Issue 11, 2016, Pages

  Chaikuad, Apirat ^a   Bullock, Alex N ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

SMAD PROTEIN; TRANSFORMING GROWTH FACTOR BETA;

DOWN REGULATION; METABOLISM; PROTEIN CONFORMATION; SIGNAL TRANSDUCTION;

DOWN-REGULATION; PROTEIN CONFORMATION; SIGNAL TRANSDUCTION; SMAD PROTEINS; TRANSFORMING GROWTH FACTOR BETA;

EID: 84994666748     PISSN: None     EISSN: 19430264     Source Type: Journal    
DOI: 10.1101/cshperspect.a022111     Document Type: Article

References (91)

1. Abdollah S, Macias-Silva M, Tsukazaki T, Hayashi H, Attisano L,Wrana JL. (1997). TβRI phosphorylation of Smad2 on Ser465 and Ser467 is required for Smad2-Smad4 complex formation and signaling. J Biol Chem 272: 27678-27685.
2. Alarcon C, Zaromytidou AI, Xi Q, Gao S, Yu J, Fujisawa S, Barlas A, Miller AN, Manova-Todorova K, Macias MJ, et al. (2009). Nuclear CDKs drive Smad transcriptional activation and turnover in BMP and TGF-β pathways. Cell 139: 757-769.
3. Aragon E, Goerner N, Zaromytidou AI, Xi Q, Escobedo A, Massagué J, Macias MJ. (2011). A Smad action turnover switch operated by WWdomain readers of a phosphoserine code. Genes Dev 25: 1275-1288.
4. Aragon E, Goerner N, Xi Q, Gomes T, Gao S, Massagué J, Macias MJ. (2012). Structural basis for the versatile interactions of Smad7 with regulatorWWdomains in TGF-β pathways. Structure 20: 1726-1736.
5. Baburajendran N, Palasingam P, Narasimhan K, Sun W, Prabhakar S, Jauch R, Kolatkar PR. (2010). Structure of Smad1 MH1/DNA complex reveals distinctive rearrangements of BMP and TGF-β effectors. Nucleic Acids Res 38: 3477-3488.
6. Baburajendran N, Jauch R, Tan CY, Narasimhan K, Kolatkar PR. (2011). Structural basis for the cooperative DNA recognition by Smad4 MH1 dimers. Nucleic Acids Res 39: 8213-8222.
7. Bork P, Sudol M. (1994). TheWWdomain: A signalling site in dystrophin? Trends Biochem Sci 19: 531-533.
8. Buczkowicz P, Hoeman C, Rakopoulos P, Pajovic S, Letourneau L, Dzamba M, Morrison A, Lewis P, Bouffet E, Bartels U, et al. (2014). Genomic analysis of diffuse intrinsic pontine gliomas identifies three molecular subgroups and recurrent activating ACVR1 mutations. Nat Genet 46: 451-456.
9. Chacko BM, Qin B, Correia JJ, Lam SS, de Caestecker MP, Lin K. (2001). The L3 loop and C-terminal phosphorylation jointly define Smad protein trimerization.Nat Struct Biol 8: 248-253.
10. Chacko BM, Qin BY, Tiwari A, Shi G, Lam S, Hayward LJ, De Caestecker M, Lin K. (2004). Structural basis of heteromeric Smad protein assembly in TGF-β signaling. Mol Cell 15: 813-823.
11. Chai J,Wu JW, Yan N,Massagué J, Pavletich NP, Shi Y. (2003). Features of a Smad3 MH1-DNA complex. Roles of water and zinc in DNA binding. J Biol Chem 278: 20327-20331.
12. Chaikuad A, Alfano I, Kerr G, Sanvitale CE, Boergermann JH, Triffitt JT, von Delft F, Knapp S, Knaus P, Bullock AN. (2012). Structure of the bone morphogenetic protein receptor ALK2 and implications for fibrodysplasia ossificans progressiva. J Biol Chem 287: 36990-36998.
13. Chen YG, Massagué J. (1999). Smad1 recognition and activation by the ALK1 group of transforming growth factor-β family receptors. J Biol Chem 274: 3672-3677.
14. Chen YG, Hata A, Lo RS, Wotton D, Shi Y, Pavletich N, Massagué J. (1998). Determinants of specificity in TGF-β signal transduction. Genes Dev 12: 2144-2152.
15. Chen YG, Wang Z, Ma J, Zhang L, Lu Z. (2007). Endofin, a FYVE domain protein, interacts with Smad4 and facilitates transforming growth factor-β signaling. J Biol Chem 282: 9688-9695.
16. ChenW, Lam SS, Srinath H, Jiang Z, Correia JJ, Schiffer CA, Fitzgerald KA, Lin K, Royer WE Jr. (2008). Insights into interferon regulatory factor activation from the crystal structure of dimeric IRF5. Nat Struct Mol Biol 15: 1213-1220.
17. Chong PA, Lin H, Wrana JL, Forman-Kay JD. (2006). An expanded WW domain recognition motif revealed by the interaction between Smad7 and the E3 ubiquitin ligase Smurf2. J Biol Chem 281: 17069-17075.
18. Chong PA, Lin H, Wrana JL, Forman-Kay JD. (2010). Coupling of tandem Smad ubiquitination regulatory factor (Smurf )WWdomains modulates target specificity. Proc Natl Acad Sci 107: 18404-18409.
19. Correia JJ, Chacko BM, Lam SS, Lin K. (2001). Sedimentation studies reveal a direct role of phosphorylation in Smad3:Smad4 homo- and hetero-trimerization. Biochemistry 40: 1473-1482.
20. Daly AC, Randall RA, Hill CS. (2008). Transforming growth factor b-induced Smad1/5 phosphorylation in epithelial cells is mediated by novel receptor complexes and is essential for anchorage-independent growth. Mol Cell Biol 28: 6889-6902.
21. Deheuninck J, Luo K. (2009). Ski and SnoN, potent negative regulators of TGF-β signaling. Cell Res 19: 47-57.
22. Dennler S, Huet S, Gauthier JM. (1999). A short amino-acid sequence in MH1 domain is responsible for functional differences between Smad2 and Smad3. Oncogene 18: 1643-1648.
23. Durocher D, Taylor IA, Sarbassova D, Haire LF,Westcott SL, Jackson SP, Smerdon SJ, Yaffe MB. (2000). The molecular basis of FHA domain:phosphopeptide binding specificity and implications for phospho-dependent signaling mechanisms. Mol Cell 6: 1169-1182.
24. Endicott JA, Noble ME, Johnson LN. (2012). The structural basis for control of eukaryotic protein kinases. Annu Rev Biochem 81: 587-613.
25. Feng XH, Derynck R. (1997). A kinase subdomain of transforming growth factor-β (TGF-β) type I receptor determines the TGF-β intracellular signaling specificity. EMBO J 16: 3912-3923.
26. Ferrand N, Atfi A, Prunier C. (2010). The oncoprotein c-Ski functions as a direct antagonist of the transforming growth factor-β type I receptor. Cancer Res 70: 8457-8466.
27. Fontebasso AM, Papillon-Cavanagh S, Schwartzentruber J, Nikbakht H, Gerges N, Fiset PO, Bechet D, Faury D, De Jay N, Ramkissoon LA, et al. (2014). Recurrent somatic mutations in ACVR1 in pediatric midline high-grade astrocytoma. Nat Genet 46: 462-466.
28. Fukuda T, Kanomata K, Nojima J, Kokabu S, Akita M, Ikebuchi K, Jimi E, Komori T, Maruki Y, Matsuoka M, et al. (2008). A unique mutation of ALK2, G356D, found in a patient with fibrodysplasia ossificans progressiva is a moderately activated BMP type I receptor. Biochem Biophys Res Commun 377: 905-909.
29. Fukuda T, Kohda M, Kanomata K, Nojima J, Nakamura A, Kamizono J, Noguchi Y, Iwakiri K, Kondo T, Kurose J, et al. (2009). Constitutively activated ALK2 and increased SMAD1/5 cooperatively induce bone morphogenetic protein signaling in fibrodysplasia ossificans progressiva. J Biol Chem 284: 7149-7156.
30. Gaarenstroom T, Hill CS. (2014). TGF-β signaling to chromatin: How Smads regulate transcription during self-renewal and differentiation. Semin Cell Dev Biol 32C: 107-118.
31. Gao S, Alarcon C, Sapkota G, Rahman S, Chen PY, Goerner N, Macias MJ, Erdjument-Bromage H, Tempst P, Massagué J. (2009). Ubiquitin ligase Nedd4L targets activated Smad2/3 to limit TGF-β signaling. Mol Cell 36: 457-468.
32. Han S, Loulakis P, Griffor M, Xie Z. (2007). Crystal structure of activin receptor type IIB kinase domain from human at 2.0 angstrom resolution. Protein Sci 16: 2272-2277.
33. Hatsell SJ, Idone V,Wolken DM, Huang L, Kim HJ,Wang L, Wen X, Nannuru KC, Jimenez J, Xie L, et al. (2015). ACVR1R206H receptor mutation causes fibrodysplasia ossificans progressiva by imparting responsiveness to activin A. Sci Transl Med 7: 303ra137.
34. Hino K, Ikeya M, Horigome K, Matsumoto Y, Ebise H, Nishio M, Sekiguchi K, Shibata M, Nagata S, Matsuda S, et al. (2015). Neofunction of ACVR1 in fibrodysplasia ossificans progressiva. Proc Natl Acad Sci 112: 15438-15443.
35. Huse M, Chen YG, Massagué J, Kuriyan J. (1999). Crystal structure of the cytoplasmic domain of the type I TGF β receptor in complex with FKBP12. Cell 96: 425-436.
36. Huse M, Muir TW, Xu L, Chen YG, Kuriyan J, Massagué J. (2001). The TGF β receptor activation process: An inhibitor-to substrate-binding switch. Mol Cell 8: 671-682.
37. Inamitsu M, Itoh S, Hellman U, Ten Dijke P, Kato M. (2006). Methylation of Smad6 by protein arginine N-methyltransferase 1. FEBS Lett 580: 6603-6611.
38. Kang JS, Saunier EF, Akhurst RJ, Derynck R. (2008). The type I TGF-β receptor is covalently modified and regulated by sumoylation. Nat Cell Biol 10: 654-664.
39. Kaplan FS, Xu M, Seemann P, Connor JM, Glaser DL, Carroll L, Delai P, Fastnacht-Urban E, Forman SJ, Gillessen-Kaesbach G, et al. (2009). Classic and atypical fibrodysplasia ossificans progressiva (FOP) phenotypes are caused by mutations in the bone morphogenetic protein (BMP) type I receptor ACVR1. Hum Mutat 30: 379-390.
40. Kato Y, Nagata K, Takahashi M, Lian L, Herrero JJ, Sudol M, Tanokura M. (2004). Common mechanism of ligand recognition by group II/III WWdomains: Redefining their functional classification. J Biol Chem 279: 31833-31841.
41. Kawabata M, Inoue H, Hanyu A, Imamura T, Miyazono K. (1998). Smad proteins exist as monomers in vivo and undergo homo- and hetero-oligomerization upon activation by serine/threonine kinase receptors. EMBO J 17: 4056-4065.
42. Krupa A, Preethi G, Srinivasan N. (2004). Structural modes of stabilization of permissive phosphorylation sites in protein kinases: Distinct strategies in Ser/Thr and Tyr kinases. J Mol Biol 339: 1025-1039.
43. Kuratomi G, Komuro A, Goto K, Shinozaki M, Miyazawa K, Miyazono K, Imamura T. (2005). NEDD4-2 (neural precursor cell expressed, developmentally down-regulated 4-2) negatively regulates TGF-β (transforming growth factor-β) signalling by inducing ubiquitin-mediated degradation of Smad2 and TGF-β type I receptor. Biochem J 386: 461-470.
44. Lagna G, Hata A, Hemmati-Brivanlou A, Massagué J. (1996). Partnership between DPC4 and SMAD proteins in TGFβ signalling pathways. Nature 383: 832-836.
45. Lawler S, Feng XH, Chen RH, Maruoka EM, Turck CW, Griswold-Prenner I, Derynck R. (1997). The type II transforming growth factor-β receptor autophosphorylates not only on serine and threonine but also on tyrosine residues. J Biol Chem 272: 14850-14859.
46. Lee MK, Pardoux C, Hall MC, Lee PS,Warburton D, Qing J, Smith SM, Derynck R. (2007). TGF-β activates Erk MAP kinase signalling through direct phosphorylation of ShcA. EMBO J 26: 3957-3967.
47. Lin X, Liang M, Liang YY, Brunicardi FC, Melchior F, Feng XH. (2003). Activation of transforming growth factor-β signaling by SUMO-1 modification of tumor suppressor Smad4/DPC4. J Biol Chem 278: 18714-18719.
48. Lo RS, Chen YG, Shi Y, Pavletich NP, Massagué J. (1998). The L3 loop: A structural motif determining specific interactions between SMAD proteins and TGF-β receptors. EMBO J 17: 996-1005.
49. Macias-Silva M, Hoodless PA, Tang SJ, Buchwald M,Wrana JL. (1998). Specific activation of Smad1 signaling pathways by the BMP7 type I receptor, ALK2. J Biol Chem 273: 25628-25636.
50. Manning G,Whyte DB,Martinez R, Hunter T, Sudarsanam S. (2002). The protein kinase complement of the human genome. Science 298: 1912-1934.
51. Massagué J. (2012). TGFβ signalling in context. Nat Rev Mol Cell Biol 13: 616-630.
52. Michnick SW, Rosen MK, Wandless TJ, Karplus M, Schreiber SL. (1991). Solution structure of FKBP, a rotamase enzyme and receptor for FK506 and rapamycin. Science 252: 836-839.
53. Miura S, Takeshita T, Asao H, Kimura Y,Murata K, Sasaki Y, Hanai JI, Beppu H, Tsukazaki T, Wrana JL, et al. (2000). Hgs (Hrs), a FYVE domain protein, is involved in Smad signaling through cooperation with SARA. Mol Cell Biol 20: 9346-9355.
54. Moustakas A, Heldin CH. (2002). From mono- to oligo-Smads: The heart of the matter in TGF-β signal transduction. Genes Dev 16: 1867-1871.
55. Nyman T, Tresaugues L, Welin M, Lehtio L, Flodin S, Persson C, Johansson I, Hammarstrom M, Nordlund P. (2010). The crystal structure of the Dachshund domain of human SnoN reveals flexibility in the putative protein interaction surface. PLoS ONE 5: e12907.
56. Persson U, Izumi H, Souchelnytskyi S, Itoh S, Grimsby S, Engstrom U, Heldin CH, Funa K, ten Dijke P. (1998). The L45 loop in type I receptors for TGF-β family members is a critical determinant in specifying Smad isoform activation. FEBS Lett 434: 83-87.
57. Qin B, Lam SS, Lin K. (1999). Crystal structure of a transcriptionally active Smad4 fragment. Structure 7: 1493-1503.
58. Qin BY, Lam SS, Correia JJ, Lin K. (2002). Smad3 allostery links TGF-β receptor kinase activation to transcriptional control. Genes Dev 16: 1950-1963.
59. Qin BY, Liu C, Lam SS, Srinath H, Delston R, Correia JJ, Derynck R, Lin K. (2003). Crystal structure of IRF-3 reveals mechanism of autoinhibition and virus-induced phosphoactivation. Nat Struct Biol 10: 913-921.
60. Qin BY, Liu C, Srinath H, Lam SS, Correia JJ, Derynck R, Lin K. (2005). Crystal structure of IRF-3 in complex with CBP. Structure 13: 1269-1277.
61. Randall RA, Germain S, Inman GJ, Bates PA, Hill CS. (2002). Different Smad2 partners bind a common hydrophobic pocket in Smad2 via a defined proline-rich motif. EMBO J 21: 145-156.
62. Ross S, Hill CS. (2008). How the Smads regulate transcription. Int J Biochem Cell Biol 40: 383-408.
63. Shen Q, Little SC, Xu M,Haupt J, Ast C, Katagiri T,Mundlos S, Seemann P, Kaplan FS, Mullins MC, et al. (2009). The fibrodysplasia ossificans progressiva R206H ACVR1 mutation activates BMP-independent chondrogenesis and zebrafish embryo ventralization. J Clin Invest 119: 3462-3472.
64. Shi Y, Hata A, Lo RS, Massagué J, Pavletich NP. (1997). A structural basis for mutational inactivation of the tumour suppressor Smad4. Nature 388: 87-93.
65. Shi Y,Wang YF, Jayaraman L, Yang H, Massagué J, Pavletich NP. (1998). Crystal structure of a Smad MH1 domain bound to DNA: Insights on DNA binding in TGF-β signaling. Cell 94: 585-594.
66. ShiW, Chang C, Nie S, Xie S,Wan M, Cao X. (2007). Endofin acts as a Smad anchor for receptor activation in BMP signaling. J Cell Sci 120: 1216-1224.
67. Shore EM, Xu M, Feldman GJ, Fenstermacher DA, Cho TJ, Choi IH, Connor JM, Delai P, Glaser DL, LeMerrer M, et al. (2006). A recurrent mutation in the BMP type I receptor ACVR1 causes inherited and sporadic fibrodysplasia ossificans progressiva. Nat Genet 38: 525-527.
68. Song GA, Kim HJ, Woo KM, Baek JH, Kim GS, Choi JY, Ryoo HM. (2010). Molecular consequences of the ACVR1R206H mutation of fibrodysplasia ossificans progressiva. J Biol Chem 285: 22542-22553.
69. Souchelnytskyi S, ten Dijke P, Miyazono K, Heldin CH. (1996). Phosphorylation of Ser165 in TGF-β type I receptor modulates TGF-β1-induced cellular responses. EMBO J 15: 6231-6240.
70. Souchelnytskyi S, Tamaki K, Engstrom U, Wernstedt C, ten Dijke P, Heldin CH. (1997). Phosphorylation of Ser465 and Ser467 in the C terminus of Smad2 mediates interaction with Smad4 and is required for transforming growth factor-β signaling. J Biol Chem 272: 28107-28115.
71. Sudol M. (2012). WWdomains in the heart of Smad regulation. Structure 20: 1619-1620.
72. Suzuki H, Yagi K, Kondo M, Kato M, Miyazono K, Miyazawa K. (2004). c-Ski inhibits the TGF-β signaling pathway through stabilization of inactive Smad complexes on Smad-binding elements. Oncogene 23: 5068-5076.
73. Takahasi K, Suzuki NN, Horiuchi M, Mori M, Suhara W, Okabe Y, Fukuhara Y, Terasawa H, Akira S, Fujita T, et al. (2003). X-ray crystal structure of IRF-3 and its functional implications. Nat Struct Biol 10: 922-927.
74. Takahasi K, Horiuchi M, Fujii K, Nakamura S, Noda NN, Yoneyama M, Fujita T, Inagaki F. (2010). Ser386 phosphorylation of transcription factor IRF-3 induces dimerization and association with CBP/p300 without overall conformational change. Genes Cells 15: 901-910.
75. Takeda M, Mizuide M, Oka M, Watabe T, Inoue H, Suzuki H, Fujita T, Imamura T, Miyazono K, Miyazawa K. (2004). Interaction with Smad4 is indispensable for suppression of BMP signaling by c-Ski. Mol Biol Cell 15: 963-972.
76. Taylor KR, Mackay A, Truffaux N, Butterfield YS,Morozova O, Philippe C, Castel D, Grasso CS, Vinci M, Carvalho D, et al. (2014). Recurrent activating ACVR1 mutations in diffuse intrinsic pontine glioma. Nat Genet 46: 457-461.
77. Tsukazaki T, Chiang TA, Davison AF, Attisano L, Wrana JL. (1998). SARA, a FYVE domain protein that recruits Smad2 to the TGFβ receptor. Cell 95: 779-791.
78. Ueki N, Hayman MJ. (2003). Direct interaction of Ski with either Smad3 or Smad4 is necessary and sufficient for Ski-mediated repression of transforming growth factorb signaling. J Biol Chem 278: 32489-32492.
79. van Dinther M, Visser N, de Gorter DJ, Doorn J, Goumans MJ, de Boer J, ten Dijke P. (2010). ALK2 R206H mutation linked to fibrodysplasia ossificans progressiva confers constitutive activity to the BMP type I receptor and sensitizes mesenchymal cells to BMP-induced osteoblast differentiation and bone formation. J Bone Miner Res 25: 1208-1215.
80. Wang G, Li C,Wang Y, Chen G. (2013). Cooperative assembly of Co-Smad4 MH1 with R-Smad1/3 MH1 on DNA: A molecular dynamics simulation study. PLoS ONE 8: e53841.
81. Wieser R, Wrana JL, Massagué J. (1995). GS domain mutations that constitutively activate TβRI, the downstream signaling component in the TGF-β receptor complex. EMBO J 14: 2199-2208.
82. Wilson JJ, Malakhova M, Zhang R, Joachimiak A, Hegde RS. (2004). Crystal structure of the dachshund homology domain of human SKI. Structure 12: 785-792.
83. Wrana JL, Attisano L,Wieser R, Ventura F,Massagué J. (1994). Mechanism of activation of the TGF-β receptor. Nature 370: 341-347.
84. Wu G, Chen YG, Ozdamar B, Gyuricza CA, Chong PA, Wrana JL, Massagué J, Shi Y. (2000). Structural basis of Smad2 recognition by the Smad anchor for receptor activation. Science 287: 92-97.
85. Wu JW, Hu M, Chai J, Seoane J, Huse M, Li C, Rigotti DJ, Kyin S,MuirTW, Fairman R, et al. (2001). Crystal structure of a phosphorylated Smad2. Recognition of phosphoserine by the MH2 domain and insights on Smad function in TGF-β signaling. Mol Cell 8: 1277-1289.
86. Wu JW, Krawitz AR, Chai J, Li W, Zhang F, Luo K, Shi Y. (2002). Structural mechanism of Smad4 recognition by the nuclear oncoprotein Ski: Insights on Ski-mediated repression of TGF-β signaling. Cell 111: 357-367.
87. Wu G, Diaz AK, Paugh BS, Rankin SL, Ju B, Li Y, Zhu X, Qu C, Chen X, Zhang J, et al. (2014). The genomic landscape of diffuse intrinsic pontine glioma and pediatric non-brainstem high-grade glioma. Nat Genet 46: 444-450.
88. Xu J, Wang AH, Oses-Prieto J, Makhijani K, Katsuno Y, Pei M, Yan L, Zheng YG, Burlingame A, Bruckner K, et al. (2013). Arginine methylation initiates BMP-induced Smad signaling. Mol Cell 51: 5-19.
89. Xu P, Bailey-Bucktrout S, Xi Y, Xu D, Du D, Zhang Q, Xiang W, Liu J, Melton A, Sheppard D, et al. (2014). Innate antiviral host defense attenuates TGF-β function through IRF3-mediated suppression of Smad signaling. Mol Cell 56: 723-737.
90. Yagi K, Goto D, Hamamoto T, Takenoshita S, Kato M, Miyazono K. (1999). Alternatively spliced variant of Smad2 lacking exon 3. Comparison with wild-type Smad2 and Smad3. J Biol Chem 274: 703-709.
91. Zawel L, Dai JL, Buckhaults P, Zhou S, Kinzler KW, Vogelstein B, Kern SE. (1998). Human Smad3 and Smad4 are sequence-specific transcription activators. Mol Cell 1: 611-617.